NCT02625207View on ClinicalTrials.gov

THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC

PHASE1CompletedINTERVENTIONAL

Enrollment

47

Participants

Timeline

Start Date

November 6, 2015

Primary Completion Date

March 26, 2016

Study Completion Date

March 26, 2016

Conditions

Healthy Subjects

Interventions

DRUG

Maraviroc (Part 1)

300 mg twice daily x 5 days

DRUG

Maraviroc (Part 2)

150 mg once daily x 10 days

DRUG

Darunavir/cobicistat (Part 2)

800/150 mg once daily x 10 days

Trial Locations (1)

06511

Pfizer New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

ViiV Healthcare

INDUSTRY